About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
European Journal of Cancer
›
Top Articles
European Journal of Cancer
Oncology
7.5
(top 3%)
Impact Factor
8.2
(top 3%)
extended IF
235
(top 1%)
H-Index
10.1K
authors
14.6K
papers
550K
citations
11.2K
citing journals
176.9K
citing authors
Most Cited Articles of European Journal of Cancer
Title
Year
Citations
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
2009
16.1K
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
2013
3.8K
Radiomics: extracting more information from medical images using advanced feature analysis
2012
2.3K
A survey of telomerase activity in human cancer
1997
2.2K
Estimates of cancer incidence and mortality in Europe in 2008
2010
1.7K
EGFR and cancer prognosis
2001
1.5K
Cancer burden in the year 2000. The global picture
2001
1.4K
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
1999
1.3K
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
2001
1.3K
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
2016
1.2K
Curcumin: the story so far
2005
1.2K
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities
2001
1.1K
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
1994
1.1K
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
2018
1.1K
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy
2006
1.1K
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
1998
1K
Phase III trial of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal (PM) Patients (PTS) with hormone-dependent Advanced Breast Cancer (ABC)
2001
933
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
2005
848
Correlation of Immunohistochemistry (IHC) and gene microarray analysis of breast biopsies from a preoperative endocrine therapy trial
2001
820
Etoposide: four decades of development of a topoisomerase II inhibitor
1998
728
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2011
727
The role of IL-6 and STAT3 in inflammation and cancer
2005
714
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
2006
701
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group
2010
665
EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary
2009
643
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.